[开放获取]   从发病机制认知变化看慢性自发性荨麻疹治疗进展

doi:10.35541/cjd.20230102

Abstract

Abstract: 【Abstract】 Mast cells, autoantibodies, inflammatory cells, coagulation cascade, complement system and nervous system are all involved in the complex pathogenesis of chronic spontaneous urticaria （CSU）, while mast cells play a pivotal role in it. With deeper understanding of the pathogenesis of CSU, cutting-edge therapeutic methods are gradually being used in clinical practice. Nowadays, pharmacotherapyeutic studies are more focused on accurately modulating the pathological state of mast cells. This review summarizes recent advances in the pathogenesis of and medicines for CSU.

Key words: Urticaria, Mast cells, Immunoglobulin E, Diagnosis, Treatment, Chronic spontaneous urticaria, Pathogenesis

Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis[J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.doi:10.35541/cjd.20230102

References ［38］

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［2］	Zuberbier T, Bindslev⁃Jensen C, Canonica W, et al. EAACI/GA2LEN/EDF guideline: management of urticaria［J］. Allergy, 2006,61（3）:321⁃331. doi: 10.1111/j.1398⁃9995.2005.00962.x.
［3］	Zuberbier T, Asero R, Bindslev⁃Jensen C, et al. EAACI/GA（2）LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria［J］. Allergy, 2009,64（10）:1417⁃1426. doi: 10.1111/j.1398⁃9995.2009.02179.x.
［4］	Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2014,69（7）:e1⁃e29. doi: 10.1111/all.12370.
［5］	Kolkhir P, Giménez⁃Arnau AM, Kulthanan K, et al. Urticaria［J］. Nat Rev Dis Primers, 2022,8（1）:61. doi: 10.1038/s41572⁃022⁃00389⁃z.
［6］	Giménez⁃Arnau AM, DeMontojoye L, Asero R, et al. The pathogenesis of chronic spontaneous urticaria: the role of infiltrating cells［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2195⁃2208. doi: 10.1016/j.jaip.2021.03.033.
［7］	Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum（CIA）update 2020［J］. Int Arch Allergy Immunol, 2020,181（5）:321⁃333. doi: 10.1159/000507218.
［8］	Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous urticaria: when and which［J］. J Allergy Clin Immunol Pract, 2021,9（3）:1067⁃1078. doi: 10.1016/ j.jaip.2020.11.043.
［9］	Altrichter S, Zampeli V, Ellrich A, et al. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria［J］. Allergy, 2020,75（12）:3208⁃3215. doi: 10.1111/all.14412.
［10］	Curto⁃Barredo L, Pujol RM, Roura⁃Vives G, et al. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response［J］. Eur J Dermatol, 2019,29（6）:627⁃635. doi: 10.1684/ejd.2019.3674.
［11］	Hershko AY, Rivera J. Mast cell and T cell communication; amplification and control of adaptive immunity［J］. Immunol Lett, 2010,128（2）:98⁃104. doi: 10.1016/j.imlet.2009.10.013.
［12］	Zhou B, Li J, Liu R, et al. The role of crosstalk of immune cells in pathogenesis of chronic spontaneous urticaria［J］. Front Immunol, 2022,13:879754. doi: 10.3389/fimmu.2022.879754.
［13］	Yanase Y, Takahagi S, Ozawa K, et al. The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria［J］. Cells, 2021,10（7）:1759. doi: 10.3390/cells10071759.
［14］	Shtessel M, Limjunyawong N, Oliver ET, et al. MRGPRX2 activation causes increased skin reactivity in patients with chronic spontaneous urticaria［J］. J Invest Dermatol, 2021,141（3）:678⁃681.e2. doi: 10.1016/j.jid.2020.06.030.
［15］	Cao C, Roth BL. The structure, function, and pharmacology of MRGPRs［J］. Trends Pharmacol Sci, 2023,44（4）:237⁃251. doi: 10.1016/j.tips.2023.02.002.
［16］	Melikoglu M, Pala E, Bayraktar M. Etiological causes in patients with acute urticaria and angioedema: a cross⁃sectional study［J］. Allergol Immunopathol （Madr）, 2022,50（S Pt 2）:15⁃23. doi: 10.15586/aei.v50iSP2.784.
［17］	Liu ZQ, Li XX, Qiu SQ, et al. Vitamin D contributes to mast cell stabilization［J］. Allergy, 2017,72（8）:1184⁃1192. doi: 10.1111/all.13110.
［18］	Matsuo H, Yokooji T, Morita H, et al. Aspirin augments IgE⁃mediated histamine release from human peripheral basophils via Syk kinase activation［J］. Allergol Int, 2013,62（4）:503⁃511. doi: 10.2332/allergolint.13⁃OA⁃0536.
［19］	Chompunud Na Ayudhya C, Ali H. Mas⁃related G protein⁃coupled receptor⁃X2 and its role in non⁃immunoglobulin E⁃mediated drug hypersensitivity［J］. Immunol Allergy Clin North Am, 2022,42（2）:269⁃284. doi: 10.1016/j.iac.2021.12.003.
［20］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all. 15090.
［21］	Engeroff P, Vogel M. The role of CD23 in the regulation of allergic responses［J］. Allergy, 2021,76（7）:1981⁃1989. doi: 10.1111/all.14724.
［22］	中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识［J］. 中华皮肤科杂志, 2021,54（12）:1057⁃1062. doi: 10.35541/cjd.20210568.
［23］	张宇, 高迎霞, 顾宁琰, 等. 奥马珠单抗对慢性自发性荨麻疹患者的临床疗效和安全性分析［J］. 中华皮肤科杂志, 2021,54（7）:582⁃585. doi: 10.35541/cjd.20201261.
［24］	Sussman G, Hébert J, Gulliver W, et al. Omalizumab re⁃treatment and step⁃up in patients with chronic spontaneous urticaria: OPTIMA Trial［J］. J Allergy Clin Immunol Pract, 2020,8（7）:2372⁃2378.e5. doi: 10.1016/j.jaip.2020.03.022.
［25］	云玉会. 奥马珠单抗治疗慢性荨麻疹的真实世界数据的研究［D］.合肥: 安徽医科大学, 2022. doi: 10.26921/d.cnki.ganyu. 2022.000760.
［26］	Harrison CA, Bastan R, Peirce MJ, et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506［J］. Br J Pharmacol, 2007,150（4）:509⁃518. doi: 10.1038/sj.bjp.0707002.
［27］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017.
［28］	Thurmond RL. The histamine H4 receptor: from orphan to the clinic［J］. Front Pharmacol, 2015,6:65. doi: 10.3389/fphar.2015. 00065.
［29］	Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti⁃IgE antibody ligelizumab differs from omalizumab［J］. Nat Commun, 2020,11（1）:165. doi: 10.1038/s41467⁃019⁃13815⁃w.
［30］	Kuo BS, Li CH, Chen JB, et al. IgE⁃neutralizing UB⁃221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23⁃mediated IgE downregulation and relieves urticaria symptoms［J］. J Clin Invest, 2022,132（15）:e157765. doi: 10.1172/JCI15 7765.
［31］	Sun Y, Lin SY, Lan CE. Dupilumab as a rescue therapy for a chronic urticaria patient who showed secondary failure to omalizumab［J］. Kaohsiung J Med Sci, 2022,38（6）:610⁃611. doi: 10.1002/kjm2.12531.
［32］	Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine⁃refractory chronic spontaneous urticaria: a randomized phase 2 trial［J］. Nat Med, 2021,27（11）:1961⁃1969. doi: 10.1038/s41591⁃021⁃01537⁃w.
［33］	Ramirez Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin［J］. Br J Pharmacol, 2019,176（8）:1135⁃1142. doi: 10.1111/bph.14610.
［34］	Wilson LH, Eliason MJ, Leiferman KM, et al. Treatment of refractory chronic urticaria with tumor necrosis factor⁃alfa inhibitors［J］. J Am Acad Dermatol, 2011,64（6）:1221⁃1222. doi: 10.1016/j.jaad.2009.10.043.
［35］	Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria［J］. Clin Exp Allergy, 2020,50（7）:799⁃804. doi: 10. 1111/cea.13616.
［36］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［37］	Altrichter S, Staubach P, Pasha M, et al. An open⁃label, proof⁃of⁃concept study of lirentelimab for antihistamine⁃resistant chronic spontaneous and inducible urticaria［J］. J Allergy Clin Immunol, 2022,149（5）:1683⁃1690.e7. doi: 10.1016/j.jaci.2021.12.772.
［38］	Terhorst⁃Molawi D, Hawro T, Grekowitz E, et al. Anti⁃KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria［J］. Allergy, 2022. doi: 10.1111/all.15585.

[1]	Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562.
[2]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[3]	Mi Shuhong, Yu Yanqin, Hao Jinqi, Li Wei, Zhang Yang, Jia Ximei, Huang Yuxian, Sun Huaiyu, Shi Jihai. Analysis of imaging characteristics of papulopustular rosacea by high-frequency ultrasound combined with color Doppler flow imaging [J]. Chinese Journal of Dermatology, 2023, 56(6): 540-544.
[4]	Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570.
[5]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[6]	Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503.
[7]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[8]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[9]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[10]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[11]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[12]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.
[13]	Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409.
[14]	Hu Qingjie, Zhou Min, Yao Xu. Analysis of clinical characteristics of 36 patients with pyoderma gangrenosum and comparison between the PARACELSUS score and Delphi criteria for their diagnosis [J]. Chinese Journal of Dermatology, 2023, 56(5): 410-414.
[15]	Committee on Sexually Transmitted Diseases, China Dermatologist Association. Expert consensus on clinical management of serofast state in syphilis （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 383-388.

Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis

PDF

Knowledge

Abstract

Cite this article

share this article

References ［38］

Related Articles 15

Metrics

Comments

Recommended 10